Mounia Beloueche-Babari

Summary

Affiliation: Institute of Cancer Research
Country: UK

Publications

  1. ncbi Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition
    Mounia Beloueche-Babari
    Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
    Cancer Res 65:3356-63. 2005
  2. ncbi Metabolic assessment of the action of targeted cancer therapeutics using magnetic resonance spectroscopy
    M Beloueche-Babari
    Section of Magnetic Resonance, Cancer Research UK and EPSRC Cancer Imaging Centre, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Surrey SM2 5PT, UK
    Br J Cancer 102:1-7. 2010
  3. ncbi Exploiting tumor metabolism for non-invasive imaging of the therapeutic activity of molecularly targeted anticancer agents
    Mounia Beloueche-Babari
    Cancer Research UK and EPSRC Centre for Cancer Imaging, Section of Magnetic Resonance, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK
    Cell Cycle 10:2883-93. 2011
  4. ncbi Histone deacetylase inhibition increases levels of choline kinase α and phosphocholine facilitating noninvasive imaging in human cancers
    Mounia Beloueche-Babari
    Cancer Research UK and EPSRC Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
    Cancer Res 72:990-1000. 2012
  5. ncbi Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells
    Mounia Beloueche-Babari
    Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom
    Mol Cancer Ther 5:187-96. 2006
  6. ncbi Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition
    Mounia Beloueche-Babari
    Cancer Research UK and EPSRC Cancer Imaging Centre, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
    Oncotarget 1:185-97. 2010
  7. ncbi Changes in choline metabolism as potential biomarkers of phospholipase C{gamma}1 inhibition in human prostate cancer cells
    Mounia Beloueche-Babari
    Cancer Research UK Clinical Magnetic Resonance Research Group, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
    Mol Cancer Ther 8:1305-11. 2009
  8. ncbi Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts
    Yuen Li Chung
    Cancer Research UK, Biomedical Magnetic Resonance Research Group, Department of Basic Medical Sciences, St George s University of London, London, UK
    Neoplasia 10:303-13. 2008
  9. ncbi Modulation of choline kinase activity in human cancer cells observed by dynamic 31P NMR
    Cristina Gabellieri
    Cancer Research UK Clinical Magnetic Resonance Research Group, The Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK
    NMR Biomed 22:456-61. 2009

Detail Information

Publications9

  1. ncbi Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition
    Mounia Beloueche-Babari
    Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
    Cancer Res 65:3356-63. 2005
    ..Thus, phosphocholine has potential as a noninvasive pharmacodynamic marker for monitoring MAPK signaling blockade...
  2. ncbi Metabolic assessment of the action of targeted cancer therapeutics using magnetic resonance spectroscopy
    M Beloueche-Babari
    Section of Magnetic Resonance, Cancer Research UK and EPSRC Cancer Imaging Centre, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Surrey SM2 5PT, UK
    Br J Cancer 102:1-7. 2010
    ..We describe the MRS-detectable PD biomarkers resulting from the action of targeted therapeutics, and discuss their biological significance and future translation into clinical use...
  3. ncbi Exploiting tumor metabolism for non-invasive imaging of the therapeutic activity of molecularly targeted anticancer agents
    Mounia Beloueche-Babari
    Cancer Research UK and EPSRC Centre for Cancer Imaging, Section of Magnetic Resonance, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK
    Cell Cycle 10:2883-93. 2011
    ..Finally, the translation of these metabolic measurements from pre-clinical models to patients will be discussed...
  4. ncbi Histone deacetylase inhibition increases levels of choline kinase α and phosphocholine facilitating noninvasive imaging in human cancers
    Mounia Beloueche-Babari
    Cancer Research UK and EPSRC Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
    Cancer Res 72:990-1000. 2012
    ..Together, our findings provide mechanistic insights into the impact of HDAC inhibition on cancer cell metabolism and highlight PC as a candidate noninvasive imaging biomarker for monitoring the action of HDAC inhibitors...
  5. ncbi Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells
    Mounia Beloueche-Babari
    Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom
    Mol Cancer Ther 5:187-96. 2006
    ..05), whereas the levels of the remaining metabolites did not change significantly. Our results indicate that PI3K inhibition in human breast cancer cells by LY294002 and wortmannin is associated with a decrease in phosphocholine levels...
  6. ncbi Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition
    Mounia Beloueche-Babari
    Cancer Research UK and EPSRC Cancer Imaging Centre, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
    Oncotarget 1:185-97. 2010
    ..Our findings provide a basis for using metabolic changes as non-invasive indicators of Hsp90 inhibition and potentially as biomarkers of anticancer activity with Hsp90 drugs in malignant melanoma and possibly in other cancers...
  7. ncbi Changes in choline metabolism as potential biomarkers of phospholipase C{gamma}1 inhibition in human prostate cancer cells
    Mounia Beloueche-Babari
    Cancer Research UK Clinical Magnetic Resonance Research Group, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
    Mol Cancer Ther 8:1305-11. 2009
    ....
  8. ncbi Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts
    Yuen Li Chung
    Cancer Research UK, Biomedical Magnetic Resonance Research Group, Department of Basic Medical Sciences, St George s University of London, London, UK
    Neoplasia 10:303-13. 2008
    ..The phosphocholine and phosphomonoester increases may have the potential to act as pharmacodynamic markers for noninvasively monitoring tumor response after treatment with LAQ824 or other HDAC inhibitors...
  9. ncbi Modulation of choline kinase activity in human cancer cells observed by dynamic 31P NMR
    Cristina Gabellieri
    Cancer Research UK Clinical Magnetic Resonance Research Group, The Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK
    NMR Biomed 22:456-61. 2009
    ....